Dyne Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Dyne Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $24.18M.
- Dyne Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $28.19M.
- Dyne Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $157.24M.
- Dyne Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $246.41M.
- Dyne Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $52.37M, a 42.07% increase from fiscal 2022.
- Dyne Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $36.86M, a 76.56% decline from fiscal 2021.
- Dyne Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $157.24M, a 36.18% decline from fiscal 2020.
- Dyne Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $246.39M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $52.37M 10-K · filed 2024-03-05 | |
| 2023-06-30 | $24.18M 10-Q · filed 2023-10-30 | |
| 2023-03-31 | $28.19M 10-Q · filed 2023-10-30 | |
| 2022-12-31 | $36.86M 10-K · filed 2024-03-05 | |
| 2021-12-31 | $157.24M 10-K · filed 2023-03-02 | |
| 2021-03-31 | $157.24M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $246.39M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $246.41M 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |